LUX-lung 3 and LUX-lung 6 trials [44,45] were randomized studies that compared afatinib with cisplatin plus pemetrexed or cisplatin plus gemcitabine as first-line treatment in patients affected by lung adenocarcinoma harboring EGFR mutations. The gene discussed is EGFR; the disease is lung adenocarcinoma.